Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Mycobacterial infections in solid organ transplant recipients.
Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM; ESCMID Study Group of Infection in Compromised Hosts. Meije Y, et al. Clin Microbiol Infect. 2014 Sep;20 Suppl 7:89-101. doi: 10.1111/1469-0691.12641. Clin Microbiol Infect. 2014. PMID: 24707957 Free article. Review.
Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation.
Len O, Montejo M, Cervera C, Fariñas MC, Sabé N, Ramos A, Cordero E, Torre-Cisneros J, Martín-Dávila P, Azanza JR, Pahissa A, Gavaldà J; DAPTOSOT (Daptomycin in Solid Organ Transplantation) Study Group. Len O, et al. Transpl Infect Dis. 2014 Aug;16(4):532-8. doi: 10.1111/tid.12232. Epub 2014 May 19. Transpl Infect Dis. 2014. PMID: 24834833 Clinical Trial.
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y. Temkin E, et al. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01964-16. doi: 10.1128/AAC.01964-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27895014 Free PMC article.
Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Pérez F, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual Á, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group. Palacios-Baena ZR, et al. J Antimicrob Chemother. 2017 Mar 1;72(3):906-913. doi: 10.1093/jac/dkw513. J Antimicrob Chemother. 2017. PMID: 28062685 Free PMC article.
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators. Gutiérrez-Gutiérrez B, et al. Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22. Lancet Infect Dis. 2017. PMID: 28442293
Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group. Palacios-Baena ZR, et al. Clin Infect Dis. 2017 Oct 30;65(10):1615-1623. doi: 10.1093/cid/cix606. Clin Infect Dis. 2017. PMID: 29020250 Free PMC article.
ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers.
Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J. Tacconelli E, et al. Clin Microbiol Infect. 2019 Jul;25(7):807-817. doi: 10.1016/j.cmi.2019.01.005. Epub 2019 Jan 29. Clin Microbiol Infect. 2019. PMID: 30708122 Free article.
External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.
Machuca I, Gutiérrez-Gutiérrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Pérez E, Pérez-Nadales E, Castón JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual Á, Martínez-Martínez L, Rodríguez-Baño J, Torre-Cisneros J; REIPI/ESGBIS/INCREMENT Group. Machuca I, et al. Int J Antimicrob Agents. 2019 Oct;54(4):442-448. doi: 10.1016/j.ijantimicag.2019.07.017. Epub 2019 Aug 1. Int J Antimicrob Agents. 2019. PMID: 31377343
Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature.
Cano Á, Guzmán-Puche J, García-Gutiérrez M, Castón JJ, Gracia-Ahufinger I, Pérez-Nadales E, Recio M, Natera AM, Marfil-Pérez E, Martínez-Martínez L, Torre-Cisneros J. Cano Á, et al. J Glob Antimicrob Resist. 2020 Sep;22:9-12. doi: 10.1016/j.jgar.2019.11.007. Epub 2019 Nov 13. J Glob Antimicrob Resist. 2020. PMID: 31733412 Free article. Review.
364 results